Literature DB >> 436131

Predictive value of radionuclide methods in the diagnosis of unilateral renovascular hypertension.

I Arlart, J Rosenthal, W E Adam, G Bargon, H E Franz.   

Abstract

The validity of noninvasive (iodine-131 iodohippurate renogram, iodine-131 ortho-iodohippurate clearance, indium-113m EDTA--technetium-99m DTPA sequential renal scan) and invasive (xenon-133 washout) radionuclide screening tests was evaluated in the diagnosis of 105 patients with unilateral renovascular hypertension (RVH) and in 45 patients with essential hypertension (EH). In RVH positive findings on the stenosed side were noted in 73% of renograms, 73% of o-iodohippurate-clearance tests (N = 22), 81% of sequential renal scans, and 90% of xenon-washout studies (N = 67). In a subgroup of 55 retrospectively selected patients with normal or improved blood pressure following renovascular surgery, the preoperative findings had been positive on the stenosed side in 78% of renograms, 75% of o-iodohippurate-clearance tests (n = 20), 85% of sequential renal scans, and 93% of xenon-washout studies (n = 23). The sequential renal scan appears to be a sufficiently reliable method in noninvasive screening for unilateral RVH, although invasive xenon-washout studies show a higher percentage of hemodynamic alterations in the stenosed kidney. o-iodohippurate clearance tests, and in particular xenon-washout studies, can reveal arteriosclerotic lesions in the contralateral, non-stenosed kidney, which may be of importance when the decision for renovascular surgery is pending.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436131     DOI: 10.1007/bf02575372

Source DB:  PubMed          Journal:  Cardiovasc Radiol        ISSN: 0342-7196


  37 in total

1.  [The value of roentgen examination in reno-vascular hypertension (author's transl)].

Authors:  J J Bookstein
Journal:  Radiologe       Date:  1975-04       Impact factor: 0.635

2.  Critical appraisal of the renogram in renal vascular disease.

Authors:  B H STEWART; T P HAYNIE
Journal:  JAMA       Date:  1962-05-12       Impact factor: 56.272

3.  Measures of clinical efficacy. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease.

Authors:  B J McNeil; P D Varady; B A Burrows; S J Adelstein
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

4.  [Measurement of the kidney blood supply and plasma renin determination in the diagnosis of renovascular hypertension].

Authors:  I Arlart; J Rosenthal; F Nobbe; G Müssig; J Vollmar; H E Franz
Journal:  Vasa       Date:  1976       Impact factor: 1.961

5.  Intrarenal distribution of blood flow in man. A new analytical method for dye-dilution curves.

Authors:  J Takeuchi; I Ishikawa; T Inasaka; S Sakai; A Shinoda; A Takada; N Hamada
Journal:  Circulation       Date:  1970-08       Impact factor: 29.690

6.  The use of a scintillation camera system for screening of hypertensive patients.

Authors:  J M Keane; J U Schlegel
Journal:  J Urol       Date:  1972-07       Impact factor: 7.450

7.  Renovascular hypertension and autoregulation.

Authors:  F Kiil
Journal:  Scand J Clin Lab Invest       Date:  1968-12       Impact factor: 1.713

8.  Renal cortical blood flow and split function test in patients with hypertension and renal artery stenosis.

Authors:  J Ladefoged
Journal:  Acta Med Scand       Date:  1966-06

9.  Radiotechnetium renography and serial radiohippurate imaging for screening renovascular hypertension.

Authors:  L Rosenthall
Journal:  Semin Nucl Med       Date:  1974-04       Impact factor: 4.446

10.  Assessment of intrarenal perfusion with radioxenon: a critical review of analytical factors and their implications in man.

Authors:  N K Hollenberg; R Mangel; H Y Fung
Journal:  Semin Nucl Med       Date:  1976-04       Impact factor: 4.446

View more
  1 in total

Review 1.  Imaging techniques in the evaluation of pediatric hypertension.

Authors:  M J Siegel; T E St Amour; B A Siegel
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.